Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Memorial Sloan Kettering Cancer Center
With
National Institutes of Health (NIH)
Age
21–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
MSKCC Histologically confirmed ovarian, fallopian tube or primary peritoneal carcinoma.
Patient has received at least one prior platinum-containing (cisplatin or carboplatin) regimen
Age ≥ 21 years old
Karnofsky Performance Status (KPS) \> or = to 70%
Adequate hematologic, hepatic and renal function as defined below:
Hemoglobin ≥ 7.0 g/dl
Absolute neutrophil count ≥ 1,000/mm3
Platelet count ≥ 100,000/mm3
Serum creatinine ≤ 1.5 x the upper limit of normal or calculated creatinine clearance ≥ 60 mL/min
You may not be if
Prior carboplatin or cisplatin hypersensitivity reaction
Uncontrolled intercurrent illness including infection, congestive heart failure, myocardial infarction, transient ischemic attack or stroke within 6 months. Any such conditions that have occurred in the last 6 months but are no longer active at the time of registration are not considered exclusionary.
Patients receiving other investigational agents
Patients with HIV disease will be permitted, only if they are on effective antiretroviral therapy, have a CD4 count greater than 400, and have had no opportunistic infections within the past 6 months
Pregnant or lactating women
Life expectancy of less than 12 weeks
Clareo Health | Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer
